Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

A natural compound of green tea improves cognitive abilities of patients with trisomy 21

Published on: 04/06/2016 Reading time: 1 min
image

Trisomy 21 is the first genetic cause of intellectual disabilities, and currently cognitive rehabilitation is the only therapeutic approach offered to patients. A phase II clinical trial conducted by an international team involving researchers from the brain and spine Institute and from the Paris Diderot University, highlights for the first time, that epigallocatechin gallate, a natural compound present in high quantities in green tea, significantly improves patients' cognitive abilities. This improvement, which continues for six months after the treatment is stopped, is accompanied by the restoration of connectivity between certain brain areas. These results, published in Lancet Neurology magazine, open a new therapeutic approach for the treatment of intellectual disabilities associated with trisomy 21.

In France, 60 000 people are affected by trisomy 21, and one child in 1400 is born with this pathology (1/700 prior to prenatal diagnosis). Trisomy 21 is reflected, among other things, by intellectual impairment and learning and memory deficits that vary according to individuals. To improve patients' lives, cognitive rehabilitation is the only proposed approach, but its actions are limited. This chromosomal abnormality is defined by the presence of a third copy, in whole or in part, of chromosome 21, which results in the overexpression of many genes carried by this chromosome, especially Dyrk1A, a kinase which errors in gene dosage are involved in the intellectual disability observed in trisomy (3 copies), and in MRD7 syndrome (1 copy).

In a previous study published in 2009, researchers had shown, in an experimental model of trisomy, that an active ingredient present in green tea, epigallocatechin gallate, or EGCG, inhibits the activity of DYRK1A protein : animals treated as early as gestation showed morphological and cognitive changes with the recovery of normal performance in the recognition test of a new object. This discovery was then exploited to implement a clinical pilot study conducted in 30 young adult patients with trisomy 21. This study showed improved learning in treated patients.

Through these very encouraging results, researchers and clinicians have conducted a phase 2 clinical study, randomised, placebo-controlled, to test the efficiency of this natural compound in 84 patients (young adults) with trisomy 21. Researchers compared the efficiency of cognitive learning through a variety of tests, memory, language, learning ..., with or without treatment for 12 months.

The results of this study demonstrate that treated patients have better cognitive performance than those on placebo. The treatment with EGCG coupled with a daily cognitive stimulation (also carried out in the group with placebo) has a beneficial effect on memory impairment and deficits in executive function (brain processes settled to organise and solve problems) in the young adult with Down syndrome. Besides, the performance observed in treated patients lasts for 6 months after stopping treatment.

In patients with trisomy 21, the functional connectivity between certain brain areas is altered. Thanks to imaging studies, researchers highlighted an increase of this connectivity in treated patients, more significant in frontal areas and the cerebellum. The treatment also comes with the normalisation of cortical excitability.

This study is the first to show the efficiency of a compound, targeting neuroplasticity, on cognitive abilities as well as on the improvement of cerebral connectivity in patients with trisomy 21. The performance observed persists even after stopping treatment. Improve the lives of patients with trisomy 21 would thus be possible with this natural compound. Researchers now wish to start trials in children and to achieve a phase 3 clinical trial for the use of this compound extracted from green tea as a treatment for cognitive deficits in trisomy 21.

Sources

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(16)3003…
Rafael de la Torre, Susana de Sola, Magí Farré, Jesus Pujol, Joan Rodriguez, Josep María Espadaler, Klaus Langohr, Aida Cuenca-Royo, Alessandro Principe, Laura Xicota, Nathalie Janel, Silvina Catuara-Solarz, Gimena Hernandez, Gonzalo Sanchez-Benavides, Henri Bléhaut, Iván Dueñas, Laura del Hoyo, Bessy Benejam, Laura Blanco, Sebastiá Videla, Montserrat Fitó, Jean Maurice Delabar, Mara Dierssen. The Lancet Neurology.

Our news on the subject

La huntingtine est une protéine indispensable au développement embryonnaire, à la formation et au maintien du tissu cérébral.
Huntington's Disease: The Energy Hypothesis Gets Traction
Huntington's disease, a rare hereditary neurological disorder, is associated with an energy deficit that precedes the onset of symptoms and is closely linked to their progression. At Paris Brain Institute, Fanny Mochel and her colleagues are testing...
02.11.2025 Research, science & health
À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol...
07.16.2024 Research, science & health
See all our news